Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

With a test currently under FDA review, Inflammatix commences a 600 patient-strong clinical trial in emergency departments.

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – especially mRNA vaccines – will become a hot topic. Is there anything to fear ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...